The Dublin randomized controlled trial of intrapartum fetal heart rate monitoring.
In a randomized controlled trial involving 12,964 women, a policy of continuous electronic intrapartum fetal heart monitoring was compared with an alternative policy of intermittent auscultation, both policies including an option to measure fetal scalp blood pH. Women allocated to electronic fetal heart monitoring had shorter labors and received less analgesia. The caesarean delivery rates were 2.4% for electronic fetal heart monitoring and 2.2% for intermittent auscultation but this small difference arose from the identification of nearly twice as many fetuses with low scalp pH (less than 7.20) in the electronic fetal heart monitoring group. The forceps delivery rate was 8.2% in the electronic fetal heart monitoring group compared with 6.3% in the intermittent auscultation group, and this excess was explained by more instrumental deliveries prompted by fetal heart rate abnormalities. There were 14 stillbirths and neonatal deaths in each group, with a similar distribution of causes. There were no apparent differences in the rates of low Apgar scores, need for resuscitation, or transfer to the special care nursery. Cases of neonatal seizures and persistent abnormal neurological signs followed by survival were twice as frequent in the intermittent auscultation group, and this differential effect was related to duration of labor. Follow-up at 1 year of babies who survived neonatal seizures revealed three clearly abnormal infants in each group. The implications of these findings for both theory and practice are discussed.
D000328:Adult; D002986:Clinical Trials as Topic; D036861:Delivery, Obstetric; D005260:Female; D005312:Fetal Blood; D005313:Fetal Death; D005318:Fetal Heart; D005323:Fetal Monitoring; D006326:Heart Auscultation; D006339:Heart Rate; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007743:Labor, Obstetric; D049590:Postpartum Period; D011247:Pregnancy; D011897:Random Allocation; D012306:Risk; D012535:Scalp; D012640:Seizures / Q000453:epidemiology